Skip to content
10-K

Annual Report

CHINA PHARMA HOLDINGS, INC. CPHI

0001213900-26-038521

← back to feed
Filed
Apr 1, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 25, 2026 40.52M sh
Capex FY 2025 · Dec 31, 2025 $59.32K
Capex FY 2025 · Dec 31, 2024 $38.41K
Operating Cash Flow FY 2025 · Dec 31, 2025 $148.26K
Operating Cash Flow restated FY 2025 · Dec 31, 2024 −$406.06K
Short Term Debt FY 2025 · Dec 31, 2025 $1.44M
Short Term Debt FY 2025 · Dec 31, 2024 $1.14M
Cash And Equivalents FY 2025 · Dec 31, 2025 $345.11K
Cash And Equivalents restated FY 2025 · Dec 31, 2024 $626.88K
Stockholders Equity FY 2025 · Dec 31, 2025 $22.74M
Stockholders Equity FY 2025 · Dec 31, 2024 $7.75M
Stockholders Equity FY 2025 · Dec 31, 2023 $7.45M
Current Liabilities FY 2025 · Dec 31, 2025 $7.4M
Current Liabilities FY 2025 · Dec 31, 2024 $5.02M
Total Liabilities FY 2025 · Dec 31, 2025 $8.26M
Total Liabilities FY 2025 · Dec 31, 2024 $7.14M
Current Assets FY 2025 · Dec 31, 2025 $2.35M
Current Assets FY 2025 · Dec 31, 2024 $3.27M
Total Assets FY 2025 · Dec 31, 2025 $31M
Total Assets FY 2025 · Dec 31, 2024 $14.89M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.74
Eps Diluted restated FY 2025 · Dec 31, 2024 −$2.71
Eps Basic FY 2025 · Dec 31, 2025 −$0.74
Eps Basic restated FY 2025 · Dec 31, 2024 −$2.71
Sga Expense FY 2025 · Dec 31, 2025 $2.45M
Sga Expense FY 2025 · Dec 31, 2024 $1.78M
Rd Expense FY 2025 · Dec 31, 2025 $280.9K
Rd Expense FY 2025 · Dec 31, 2024 $283.94K
Net Income FY 2025 · Dec 31, 2025 −$3.19M
Net Income FY 2025 · Dec 31, 2024 −$4.74M
Operating Income FY 2025 · Dec 31, 2025 −$3.24M
Operating Income FY 2025 · Dec 31, 2024 −$4.59M
Gross Profit FY 2025 · Dec 31, 2025 −$131.95K
Gross Profit FY 2025 · Dec 31, 2024 −$1.99M
Cost Of Revenue FY 2025 · Dec 31, 2025 $4.28M
Cost Of Revenue FY 2025 · Dec 31, 2024 $6.51M
Revenue FY 2025 · Dec 31, 2025 $4.14M
Revenue FY 2025 · Dec 31, 2024 $4.53M